$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018
[Report Updated: 20-11-2018]

Published by Global Markets Direct: 20 Nov 2018 | 227553 | In Stock
Related Topics: Arthritis , Breast Cancer , Cancer , Colorectal Cancer , Dermatology , Immunology , Infectious Disease , Melanoma , Multiple Myeloma , Myeloma , Ophthalmology , Pancreatic Cancer , Pulmonary , Respiratory

Introduction

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Integrin Alpha V - Pipeline Review, H2 2018'; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

The report 'Integrin Alpha V - Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 6 and 18 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Persistent Corneal Epithelial Defects, Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Metastatic Melanoma, Pancreatic Cancer, Wounds, Age Related Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Malabsorption Syndrome, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Sepsis and Venous Leg Ulcers (Crural Ulcer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development

    Biogen Inc

    BioMAS Ltd

    BrightGene Bio-Medical Technology Co Ltd

    Factor Therapeutics Ltd

    MedImmune LLC

    Merck & Co Inc

    Merck KGaA

    Morphic Therapeutic Inc

    Pliant Therapeutics Inc

    SciFluor Life Sciences LLC

    Tasly Pharmaceutical Group Co Ltd

    Vascular Pharmaceuticals Inc

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles

    264-RAD - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    abituzumab - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AS-101 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BAT-2094 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BG-00011 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BGC-0222 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    C-16Y - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    cilengitide - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CWHM-12 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MK-0429 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MSP-68 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NOD-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    OCU-200 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PLN-74809 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Proagio - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RSF-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SF-0166 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Antagonize ITGAV and ITGB6 for Fibrosis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    tetraiodothyroacetic acid - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VF-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VF-003 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VF-004 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VPI-2690B - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products

    Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones

    Featured News & Press Releases

    Oct 09, 2018: Merck KGaA to announce data of Abituzumab at ESMO 2018 Congress

    Oct 04, 2018: Factor Therapeutics announce treatment completion marks milestone in Phase 2 clinical trial

    Oct 02, 2018: Factor Therapeutics provides shareholder update Q3 2018

    Sep 05, 2018: Factor Therapeutics announced phase 2 clinical trial for venous leg ulcers nears completion

    Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

    Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

    Jul 16, 2018: Factor Therapeutics: Recruitment Completed in VF00102

    Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion

    Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update

    May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase

    Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial

    Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

    Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

    Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

    Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

227553 | GMDHC1779TDB

Number of Pages

86

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29...
20 Nov 2018 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2017
Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29...
13 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017Sum...
13 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Alpha 4 Beta 7 (A4b7) Integrin Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Alpha 4 Beta 7 (A4b7) Integrin Inhibitors-Pipeline Insights, 2017”, report provides...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Alpha 5 Beta 1 Integrin Receptor Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Alpha 5 Beta 1 Integrin Receptor Antagonists-Pipeline Insights, 2017”, report provi...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Alpha v Beta 3 Integrin Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Alpha v Beta 3 Integrin Antagonists-Pipeline Insights, 2017”, report provides in de...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Alpha v Beta 5 Integrin Antagonists -Pipeline Insights, 2017
DelveInsight’s, “Alpha v Beta 5 Integrin Antagonists-Pipeline Insights, 2017”, report provides in de...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016SummaryGlobal ...
30 Dec 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2016Sum...
30 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipel...
09 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...